{"id":2345,"date":"2020-06-15T00:00:00","date_gmt":"2020-06-15T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2345"},"modified":"2020-06-15T00:00:00","modified_gmt":"2020-06-15T00:00:00","slug":"centogene-informa-los-resultados-financieros-y-el-progreso-corporativo-del-primer-trimestre-de-2020","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/es\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/","title":{"rendered":"CENTOGENE informa los resultados financieros y el progreso corporativo del primer trimestre de 2020"},"content":{"rendered":"<p>Cambridge, MA, EE. UU. y Rostock\/Berl\u00edn, Alemania, 15 de junio de 2020 (Globe Newswire) \u2013 Centogene NV (Nasdaq: CNTG), una empresa en fase comercial centrada en enfermedades raras que transforma datos cl\u00ednicos y gen\u00e9ticos del mundo real en informaci\u00f3n \u00fatil para pacientes, m\u00e9dicos y compa\u00f1\u00edas farmac\u00e9uticas, proporcion\u00f3 hoy una actualizaci\u00f3n sobre su progreso corporativo e inform\u00f3 sus resultados financieros para el trimestre finalizado el 31 de marzo de 2020.<\/p>\n<ul>\n<li>12,1 millones de euros en ingresos, un aumento de 13% en comparaci\u00f3n con los tres meses finalizados el 31 de marzo de 2019<\/li>\n<li>Expansi\u00f3n continua de la plataforma global patentada de enfermedades raras con aproximadamente 3.000 millones de puntos de datos ponderados de m\u00e1s de 530.000 pacientes que representan a 120 pa\u00edses diferentes al 31 de marzo de 2020<\/li>\n<li>M\u00e1s de 60 programas de biomarcadores, con m\u00e1s de 25 programas de biomarcadores (que cubren m\u00e1s de 22 enfermedades) que han completado la primera validaci\u00f3n con espectrometr\u00eda de masas al 31 de marzo de 2020<\/li>\n<li>Ampliaci\u00f3n de nuestras pruebas de COVID-19 y comienzo de la producci\u00f3n y distribuci\u00f3n de un kit de recolecci\u00f3n de muestras, CentoSwab\u2122, para apoyar los esfuerzos globales para abordar la pandemia.<\/li>\n<\/ul>\n<p>El Prof. Arndt Rolfs, CEO de CENTOGENE, declar\u00f3: \u201cDurante el primer trimestre de 2020, continuamos enfoc\u00e1ndonos en nuestra actividad principal: proporcionar diagn\u00f3sticos m\u00e9dicos precisos y acelerar el desarrollo de f\u00e1rmacos para enfermedades hereditarias raras, a la vez que tomamos medidas importantes para operar nuestro negocio eficazmente durante la COVID-19 y apoyar esfuerzos m\u00e1s amplios para abordar esta pandemia. Nos complace informar un crecimiento de los ingresos de 13% durante el primer trimestre de 2020, impulsado por la mejora continua de los negocios en nuestros segmentos farmac\u00e9utico y de diagn\u00f3stico\u201d.\u201d<\/p>\n<p>El profesor Arndt Rolfs continu\u00f3: \u201cMientras continuamos operando en un entorno de COVID-19, nos complace informar que, si bien nuestras r\u00e1pidas medidas iniciales permitieron que 75% de nuestros empleados trabajaran desde casa, recientemente hemos podido reincorporar a casi todo nuestro personal a la oficina mediante la implementaci\u00f3n de pruebas regulares. Adem\u00e1s, hemos aprovechado a\u00fan m\u00e1s nuestra experiencia en diagn\u00f3stico para desarrollar y ofrecer una soluci\u00f3n de prueba de SARS-CoV-2 para pacientes de todo el mundo, comenzando con el sistema de muestreo &#039;CentoSwab\u2122&#039; y terminando con la aplicaci\u00f3n desarrollada por CENTOGENE para el registro de pacientes y la elaboraci\u00f3n de informes m\u00e9dicos. Esperamos que esta soluci\u00f3n de diagn\u00f3stico ayude a las comunidades globales a comenzar a volver a la normalidad y a prevenir nuevos brotes. Con la pandemia de COVID-19 extendi\u00e9ndose por todo el mundo, hemos comenzado a ver su impacto negativo en nuestro negocio actual, pero esperamos que nuestras pruebas comerciales de COVID-19 ayuden a compensar dicho impacto negativo\u2018.\u2019<\/p>\n<h2 class=\"h3\">Respuesta \u00e1gil a la COVID-19 y continuidad de las operaciones de diagn\u00f3stico de enfermedades raras<\/h2>\n<h5>Liderando las capacidades sostenibles de pruebas de COVID-19<\/h5>\n<p>En marzo de 2020, CENTOGENE anunci\u00f3 el inicio de sus pruebas de COVID-19. Empezando con empleados y trabajadores esenciales en Rostock, Alemania, la compa\u00f1\u00eda ampli\u00f3 la oferta de pruebas a residencias de ancianos y estudiantes de secundaria en toda Alemania. Desde mayo de 2020, la compa\u00f1\u00eda ofrece sus pruebas al resto del mundo. Adem\u00e1s, desde abril de 2020, CENTOGENE ha conseguido los reactivos y suministros necesarios, como CentoSwab\u2122, para facilitar la log\u00edstica y el diagn\u00f3stico r\u00e1pido de COVID-19.<\/p>\n<h5>Adquisici\u00f3n del laboratorio de Hamburgo para ampliar las capacidades de prueba<\/h5>\n<p>En abril de 2020, CENTOGENE anunci\u00f3 la apertura de un nuevo laboratorio en Hamburgo, Alemania, para ampliar su capacidad de an\u00e1lisis del virus COVID-19. El laboratorio de Rostock seguir\u00e1 centr\u00e1ndose en la actividad principal de la empresa, las enfermedades hereditarias raras, y en sus esfuerzos de investigaci\u00f3n para el desarrollo de biomarcadores.<\/p>\n<h5><strong>Contacto con los medios<\/strong><\/h5>\n<p>CENTOGENE<br \/> Sun Kim<br \/> Director de Estrategia y Relaciones con Inversores<br \/> <a href=\"mailto:investor.relations@centogene.com\" title=\"Escribe un correo electr\u00f3nico\">relacionesconinversores@centogene.com&nbsp;<\/a><\/p>\n<p> Bridie Lawlor<br \/> Consultor\u00eda FTI<br \/> +1.917.929.5684<br \/> <a href=\"mailto:bridie.lawlor@fticonsulting.com\" title=\"Escribe un correo electr\u00f3nico\">bridie.lawlor(arroba)fticonsulting(punto)com<\/a><br \/> &nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>Durante el primer trimestre de 2020, continuamos enfoc\u00e1ndonos en nuestro negocio principal de brindar diagn\u00f3stico m\u00e9dico preciso y acelerar el desarrollo de medicamentos para enfermedades hereditarias raras, al tiempo que tomamos medidas importantes para operar nuestro negocio de manera efectiva durante COVID-19 y apoyar esfuerzos m\u00e1s amplios para abordar esta pandemia.<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2345","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/es\/centogene-informa-los-resultados-financieros-y-el-progreso-corporativo-del-primer-trimestre-de-2020\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"During the first quarter of 2020, we continued our focus on our core business of providing precise medical diagnosis of and accelerating drug development for rare hereditary diseases, while taking important steps to operate our business effectively during COVID-19 and support broader efforts to address this pandemic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/es\/centogene-informa-los-resultados-financieros-y-el-progreso-corporativo-del-primer-trimestre-de-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-15T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress\",\"datePublished\":\"2020-06-15T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/\"},\"wordCount\":552,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/\",\"name\":\"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2020-06-15T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/es\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE informa sobre los resultados financieros y el progreso corporativo del primer trimestre de 2020 | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/es\/centogene-informa-los-resultados-financieros-y-el-progreso-corporativo-del-primer-trimestre-de-2020\/","og_locale":"es_ES","og_type":"article","og_title":"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress | CENTOGENE","og_description":"During the first quarter of 2020, we continued our focus on our core business of providing precise medical diagnosis of and accelerating drug development for rare hereditary diseases, while taking important steps to operate our business effectively during COVID-19 and support broader efforts to address this pandemic.","og_url":"https:\/\/www.centogene.com\/es\/centogene-informa-los-resultados-financieros-y-el-progreso-corporativo-del-primer-trimestre-de-2020\/","og_site_name":"CENTOGENE","article_published_time":"2020-06-15T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"admincg","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress","datePublished":"2020-06-15T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/"},"wordCount":552,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/","url":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/","name":"CENTOGENE informa sobre los resultados financieros y el progreso corporativo del primer trimestre de 2020 | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2020-06-15T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Impulsar la medicina de precisi\u00f3n","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"administrador","url":"https:\/\/www.centogene.com\/es\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/posts\/2345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/comments?post=2345"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/posts\/2345\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/media?parent=2345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/categories?post=2345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/tags?post=2345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}